Pegaptanib sodium Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Pegaptanib sodium Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
74
Registered trials
55
Result records
3
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Pegaptanib sodium can convert its RNA aptamer profile and VEGF biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Pegaptanib sodium (query alias: pegaptanib) |
|---|---|
| Modality / target | RNA aptamer; VEGF; VEGF inhibitors |
| Highest global status | Approved |
| Originator | Gilead Sciences, Inc. |
| Active developers | Pfizer Inc., Gilead Sciences, Inc. |
The MCP disease footprint includes Dystrophy, Macular, Wet age-related macular degeneration. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07133438 | Phase 4 | Recruiting | 120 | Anatomical indicators-central foveal thickness |
| NCT07062055 | Phase 2 | Recruiting | 54 | Progression-free survival (PFS) |
| NCT07333287 | Phase 2 | Not yet recruiting | 38 | Progression-Free Survival（PFS） |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
A Phase IV, Open Label, Multi-center Study to Assess the Effect of Intravitreal Injections of Macugen (Pegaptanib Sodium Injection) Administered Every 6 Weeks for 48 Weeks on the Corneal Endothelium.
Phase 4; n=131; evaluation: not stated. Reported fields: -; -; Change From Baseline in Mean Endothelial Cell Density(Mean) = -35.86 cells/millimeter squared (Standard Deviation, 175.544)
Initiating Anti-VEGF Therapy for Diabetic Macular Edema: An Evidence-Based Guide
Phase 3; n=not disclosed; evaluation: not stated. Reported fields: CRT = 520 μm ; CRT = 405 μm
Effect of pegaptanib sodium 0.3 mg intravitreal injections (Macugen) in intraocular pressure: posthoc analysis from V.I.S.I.O.N. study.
Phase 2/3; n=221; evaluation: not stated. Reported fields: IOP measurements = ≥22 mm Hg
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Pegaptanib sodium addresses Dystrophy, Macular, Wet age-related macular degeneration. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—RNA aptamer—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2006-03-09 | Isis received $7 million from Drug Royalty as a partial payment for the acquisition of a part of Isis' royalty rights in Macugen | Approved | US$7.0M milestones |
| 2004-12-21 | Isis earned a $3 million milestone payment associated with the marketing clearance of Macugen by the U.S. Food and Drug Administration (FDA) for wet AMD | Approved | US$3.0M milestones |
| 2000-04-05 | Gilead Sciences and EyeTech Pharmaceuticals Announce Exclusive License of Potential New Therapy for Age-Related Macular Degeneration | Not disclosed | US$7.0M upfront; US$25.0M milestones |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Combination of a VEGF inhibitor and a complement pathway inhibitor for treating ocular disorders”. The milestone feed surfaced a patent-application signal described as “Extended, High Dose VEGF Antagonist Regimens for Treatment of Angiogenic Eye Disorders”. The milestone feed surfaced a patent-application signal described as “Nucleic acid encoding an Anti-VEGF entity and a negative complement regulator and uses thereof for the treatment of age-related macular degeneration”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
